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Original Article
Kinetics and 28-day test–retest
repeatability and reproducibility
of [11C]UCB-J PET brain imaging
Hayel Tuncel1, Ronald Boellaard1, Emma M Coomans1,
Erik FJ de Vries2 , Andor WJM Glaudemans2 ,
Paula Kopschina Feltes2, David V Garcıa2 ,
Sander CJ Verfaillie1, Emma E Wolters1,3, Steven P Sweeney4,
J Michael Ryan4, Magnus Ivarsson4, Berkley A Lynch4,
Patrick Schober5, Philip Scheltens3, Robert C Schuit1,
Albert D Windhorst1, Peter P De Deyn6,7,
Bart NM van Berckel1 and Sandeep SV Golla1
Abstract
[11C]UCB-J is a novel radioligand that binds to synaptic vesicle glycoprotein 2A (SV2A). The main objective of this study
was to determine the 28-day test–retest repeatability (TRT) of quantitative [11C]UCB-J brain positron emission tomog-
raphy (PET) imaging in Alzheimer’s disease (AD) patients and healthy controls (HCs). Nine HCs and eight AD patients
underwent two 60 min dynamic [11C]UCB-J PET scans with arterial sampling with an interval of 28 days. The optimal
tracer kinetic model was assessed using the Akaike criteria (AIC). Micro-/macro-parameters such as tracer delivery (K1)
and volume of distribution (VT) were estimated using the optimal model. Data were also analysed for simplified refer-
ence tissue model (SRTM) with centrum semi-ovale (white matter) as reference region. Based on AIC, both 1T2k_VB
and 2T4k_VB described the [
11C]UCB-J kinetics equally well. Analysis showed that whole-brain grey matter TRT for VT,
DVR and SRTM BPND were –2.2% 8.5, 0.4% 12.0 and –8.0% 10.2, averaged over all subjects. [11C]UCB-J kinetics
can be well described by a 1T2k_VB model, and a 60 min scan duration was sufficient to obtain reliable estimates for
both plasma input and reference tissue models. TRT for VT, DVR and BPND was <15% (1SD) averaged over all subjects
and indicates adequate quantitative repeatability of [11C]UCB-J PET.
Keywords
Alzheimer’s disease, [11C]UCB-J, kinetic modelling, PET, SV2A
Received 11 March 2020; Revised 19 August 2020; Accepted 27 September 2020
Introduction
Many neurodegenerative and neurological disorders
such as Alzheimer’s disease (AD),1,2 Parkinson’s dis-
ease (PD),3 epilepsy4,5 and autism spectrum disorder6
are associated with synaptic pathology. More specifi-
cally, in AD, cognitive impairment is highly correlated
with synaptic loss in the association cortex and limbic
system.7,8 Synaptic disruption is thought to be associ-
ated with toxic b-amyloid or tau oligomers and is
already observed in the earliest clinical stages of AD.9
These findings suggest that the ability to assess synaptic
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density in vivo could improve clinical research in AD
and potentially could serve as a valuable surrogate
marker for disease severity in clinical trials.
(R)-1-((3-([11C]methyl)pyridin-4-yl)methyl)-4-(3,4,5-
trifluorophenyl)pyrrolidin-2-one, also known as [11C]
UCB-J, is a radioligand with high affinity and specific-
ity for synaptic vesicle glycoprotein 2A (SV2A).10–12
[11C]UCB-J is a derivative of levetiracetam,13 an
FDA and EMA approved anti-epileptic drug. SV2A
is a member of a small family of synaptic vesicle pro-
teins and is the most widespread isoform present in
glutamatergic and GABAergic neurons.10 [11C]UCB-J
binds to SV2a in pre-synaptic terminals and, therefore,
could reflect synaptic density. Multiple preclinical
animal studies have shown that SV2A and synaptophy-
sin (a widely used presynaptic marker) have essentially
a homogeneous distribution across the brain.10
Therefore, [11C]UCB-J can be used as an imaging
agent for brain synaptic pathology in neurological dis-
eases. [11C]UCB-J was originally synthesized by
Mercier et al.14 Nabulsi et al.12 have observed high
brain uptake of [11C]UCB-J in nonhuman primates
indicating that [11C]UCB-J is a promising radioligand
targeting SV2A. The first-in-human [11C]UCB-J posi-
tron emission tomography (PET) study showed com-
parable results.11
Quantification of specific binding of [11C]UCB-J
with a validated tracer kinetic model is crucial in clin-
ical studies not only for identification of early synaptic
pathology in cross-sectional studies but also for longi-
tudinal assessment of changes in synaptic integrity. A
validated kinetic model becomes even more important
when it is used as a surrogate marker for assessing the
efficacy of disease-modifying drugs. In vivo kinetics for
[11C]UCB-J have previously been evaluated for HCs
and AD patients.15–18 For instance, Chen et al.17 eval-
uated the kinetics for [11C]UCB-J in AD patients, but
no test–retest repeatability (TRT) was reported.
Furthermore, Finnema et al.15 reported the same-day
TRT of UCB-J for 1T2k model; however, only for rel-
atively young HCs. Koole et al.18 validated the use of
simplified methods such as simplified reference tissue
model (SRTM) and standardized uptake value ratios
(SUVr) for UCB-J in relatively young HCs only. No
TRT was reported for these simplified methods in this
study nor was this assessed for AD patients. Moreover,
none of these studies addressed the long-term repeat-
ability. The TRT of plasma input models has never
been reported for AD patients. The aim of the current
study was to assess the long-term (28-day) repeatability
of various methods, such as plasma input models, and
simplified methods such as SRTM and SUVr in both
HCs and AD patients. One of the reasons for the cur-
rent study design was assessment of a clinical drug
intervention study,19 where the expected effect size
was more than 25% in a 28-day time period. Our cur-
rent TRT study with a 28-day interval between both
scans was designed to closely mimic the condition of
the intervention design.19 The effect of PET scan dura-
tion on the quantification was also evaluated, and
regional differences were assessed between HCs and
AD patients. The main aims of the current study
were: (1) TRT assessment of [11C]UCB-J binding to
SV2A using kinetic analysis with arterial input function
within the 28-day time interval; (2) TRT assessment of




In this multicentre study, 19 participants were included
who all underwent a dynamic [11C]-UCB-J PET scan
and T1-weighted MRI scan. Two PET scans were
excluded due to motion artefacts: one PET scan was
not performed due to tracer production failure and one
participant discontinued the study after the first PET
scan. Eight HCs from the Amsterdam University
Medical Center (Amsterdam UMC) and one HC
from University Medical Center Groningen (UMCG)
were included in the study as well as seven mild-to-
moderate AD patients from Amsterdam UMC and
one AD patient from UMCG. AD patients were eligi-
ble when they had a probable diagnosis of AD defined
by National Institute on Aging – Alzheimer’s
Association (NIA-AA)20 with either abnormal Ab42
in cerebrospinal fluid (CSF) (Ab42< 813 pg/mL)
21 or
an abnormal amyloid-b PET scan and a Mini-Mental
State Examination (MMSE) score between 18 and 26.
HCs were recruited through local advertisements. They
were eligible for the study if they were cognitively
normal without cognitive complaints, absence of signif-
icant impairment in cognitive functions or activities of
daily living and if the MMSE score was 27. The study
was conducted in full conformance with the principles
of the “Declaration of Helsinki” (as amended in
Tokyo, Venice, Hong Kong, Somerset-West,
Edinburgh, Washington DC, Tokyo, Seoul and
Fortaleza) and was approved by the Medical Review
and Ethics Committee (MREC) of Foundation BEBO
in Assen, and local feasibility was confirmed by the
MREC of Amsterdam UMC and by the MREC of
UMCG. Furthermore, all subjects provided written
informed consent prior to the study.
Data acquisition
[11C]UCB-J tracer was locally produced at the PET
centres of UMCG and Amsterdam UMC according
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to clinical Good Manufacturing Practice standards.
Participants underwent two dynamic PET scans on
the same PET–CT system within a given institution
(Amsterdam UMC or UMCG) with a 28-day interval.
PET scans were acquired on the Ingenuity TF PET/CT
scanner (Amsterdam UMC, Philips Medical Systems,
Best, The Netherlands) or a Biograph mCT PET-CT
scanner (UMCG, Siemens Medical Systems). Prior to
the PET scan, a low-dose computed tomography (CT)
scan was performed for attenuation correction pur-
poses. After the low-dose CT, a 90 min dynamic PET
scan was acquired after a bolus injection of 373 22
MBq [11C]UCB-J. Upon interim review (after comple-
tion of 9 HC test–retest scans), scan duration was
reduced to 60min for subsequent AD subjects after a
bolus injection of 320 39 MBq. During scanning, the
head was stabilized to reduce movement artefacts, and
subjects were positioned within the centre of axial and
transaxial fields of view, such that the orbito-meatal
line was parallel to the detectors with the use of laser
beams. T1-weighted MRI scans were also acquired for
all participants using a 3.0-T Philips Ingenuity Time-
of-Flight PET/MR scanner at Amsterdam UMC and
using a 1.5-T Siemens Aera at UMCG. At Amsterdam
UMC, PET images of 22 frames (1 15, 3 5, 3 10,
4 60, 2 150, 2 300 and 7 600 s) or 19 frames
(1 15, 3 5, 3 10, 4 60, 2 150, 2 300 and
4 600 s) with a matrix size of 128 128 90 voxels
and a final voxel size of 2 2 2 mm3 were recon-
structed using 3D row action maximum likelihood
algorithm (RAMLA). At UMCG, PET images of 25
frames (1 10, 6 5, 3 10, 4 60, 2 150, 2 300
and 7 600 s) or 22 frames (1 10, 6 5, 3 10,
4 60, 2 150, 2 300 and 4 600 s) with a matrix
size of 400 400 111 voxels and a final voxel size
of 2 2 2 mm3 were reconstructed using 3D
ordered-subsets-expectation-maximization (OSEM-
TOF) algorithm. Furthermore, all usual corrections
for attenuation, scatter, randoms, decay and dead
time were performed.
Blood data acquisition and processing
Before the PET scan, a venous catheter was inserted for
injection of the [11C]UCB-J solution. In addition, an
arterial cannula was inserted in the radial artery to col-
lect blood samples for measurement of the time course
of the tracer in plasma, including radioactive metabo-
lite analysis. A maximum of 75mL arterial blood was
sampled continuously over 60min for HCs and 30min
for AD patients, using an online detection system.22 At
set times (5, 10, 15, 20, 40, 50 and 60min), continuous
sampling was interrupted briefly for the collection of
manual blood samples (5–7mL each) to estimate the
plasma-to-whole-blood ratios and to measure plasma
metabolite fractions. Manual blood samples were col-
lected in heparin tubes and centrifuged for 5min at
5000 r/min. Plasma was separated from blood cells,
and about 1mL was diluted with 2mL water and
loaded onto a tC2 Sep-Pak cartridge (Waters,
Milford, MA), which was pre-activated by elution
with 6mL of methanol and 12mL of water, respective-
ly. The cartridge was washed with 3mL water to collect
the polar radioactive fraction. Thereafter, the tC18
Sep-Pak cartridge was eluted with 2mL of methanol
and 2mL of water at Amsterdam UMC and with
1.5ml of methanol supplemented with 0.1% diisopro-
pylamine, followed by 0.7ml of water at UMCG to
collect the fraction with intact tracer. This fraction
was further analysed by HPLC using an Ultimate
3000 system (Dionex, Sunnyvale, CA) equipped with
a 1mL loop at Amsterdam UMC, and at UMCG, a
Waters HPLC pump was used for this purpose
equipped with a 2ml loop. As a stationary phase, a
Gemini C18, 250 10mm, 5mm (Phenomenex,
Torrance, CA) was used. At Amsterdam UMC, the
mobile phase was a gradient of A¼ acetonitrile and
B¼ 0.1% diisopropylamine in water. The gradient
ran for 15min, decreasing the concentration of eluent
B from 80% to 40% in 4min, followed by 8min of
elution with 40% B at a flow rate of 3mL min1. At
UMCG, the mobile phase consisted of water/acetoni-
trile/diisopropylamine (55/45/0.1); isocratic elution at
3ml/min. The eluent was collected in 30 s fractions
with a fraction collector, and the fractions were
counted for radioactivity using a Wallac 2470 gamma
counter (Perkin Elmer, Waltham, MA).
Data analysis
Structural 3D T1-weighted MRI images were co-
registered to the PET images using Vinci v 2.56 soft-
ware. The Hammers template,23 which is incorporated
in PVElab,24 was used to delineate regions of interest
(ROIs) on the co-registered MR scan and superim-
posed onto the dynamic PET scan to obtain regional
time-activity curves (TACs). Online arterial blood
TACs were calibrated and corrected for plasma to
whole blood ratios, radiolabeled metabolites and
delay, using the information from manual blood sam-
ples. Eventually, individual metabolite-corrected
plasma input functions were generated. Various com-
partmental models25 were used to fit the regional
TACs: single tissue reversible (1T2k) and two-tissue
irreversible (2T3k) and reversible (2T4k) compartmen-
tal models, with and without blood volume (VB) as
additional fit parameter. To determine the optimal
pharmacokinetic model for in vivo kinetics of [11C]
UCB-J, the Akaike information criterion (AIC)26 was
used. Furthermore, the SRTM27 was assessed by
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comparing SRTM-derived binding potential (BPND)
with plasma input derived distribution volume ratio
(DVR). The white-matter centrum semi-ovale (SO)
was manually defined using an in-house built tool
and was considered as a reference region. Mean SO
VOI size was 5.4 2.5 cc for HCs and 4.0 2.6 cc for
AD patients. SUVr using three time intervals (40–60,
50–60 for both groups; and 70–90min only for HCs)
were also evaluated. SUVr values obtained from these
time intervals were compared with corresponding
plasma input derived DVR values.
TRT of micro-parameters (in particular the rate
constant from blood to tissue K1) and macro-
parameters (distribution volume VT, DVR and BPND)
was evaluated for the preferred model as well as the
TRT of R1 and BPND obtained from SRTM. In addi-
tion, the effect of scan duration on model preferences,
parameter estimation and TRT was assessed. Finally, a
separate comparison between HCs and AD patients
was performed to assess group differences in regional
[11C] UCB-J binding.
Statistical analysis
Statistical analyses were performed using SPSS version
20.0.0 (IBM Corp., Armonk, NY). To assess demo-
graphic, clinical and neuroimaging (i.e. SRTM-
derived BPND group comparisons) data, v
2 tests for
discrete variable, t-test and f-tests for continuous data
were used. P values smaller than 0.05 were considered
as significant. TRT was calculated using equation (1),
and variability was also assessed by measuring the dif-
ference between the test and retest parametric values.
Furthermore, the intraclass correlation coefficient
(ICC) was analysed using an average-measurement,
absolute-agreement, two-way mixed-effects model for
each parameter of interest
TRT %ð Þ ¼ ðRetest value Test valueÞðRetest value  Test valueÞ  200 (1)
Results
The clinical and demographic data are presented in
Supplementary Table 1. Net-injected doses were com-
parable between groups and between test and retest
scans (all p values> 0.05). There were no significant
differences observed in age and gender between AD
patients and HCs (p> 0.05). As expected, AD patients
had a significantly lower MMSE score compared to
HCs (p< 0.01). Please note that the results from
UMCG are presented in the supplementary figures.
Kinetic analysis
After interim review (i.e. after completion of the HC
data), scan duration was reduced to 60min for subse-
quent AD subjects. Therefore, all the results, unless
specified otherwise, are based on the 60 min PET
scan data.
[11C]UCB-J metabolized relatively fast in the plasma
with parent fractions of about 60% at 5min to only
20% after 55min post-injection (Figure 1). Based on
AIC, both 1T2k_VB and 2T4k_VB fitted the [
11C]UCB-
J regional TACs equally well (Supplementary Fig 1).
Although in case of the 2T4k_VB model, high standard
errors (>25%) were observed for binding potential
(BPND¼k3/k4) estimates. Moreover, both K1 (HC:
r2¼ 0.83, slope¼ 0.73; AD: r2¼ 0.88, slope¼ 0.84)
and VT (HC: r
2¼ 0.98, slope¼ 1.00; AD: r2¼ 0.92,
slope¼ 0.97) values correlated well between the two
models using 60min data, suggesting that a 1T2k_VB
model is sufficient to assess [11C]UCB-J in vivo kinetics
(Figure 2). UMCG data also showed a good correspon-
dence between both models (Supplementary Fig 2).
K1 values derived from the 1T2k_VB model ranged
from 0.16 0.20mL/cm3 in the white-matter SO to
0.39 0.06mL/cm3 in the whole brain grey matter.
VT (1T2k_VB model) ranged from 5.36 0.77 for the
white-matter SO to 19.32 2.59 for the whole brain
grey matter. The VT values for the SO were consider-
ably lower than the examined grey matter regions, and
there was no significant difference between AD patients
and HCs (p¼ 0.29).
Effect of the scan duration on K1 and VT values was
estimated using eight HCs obtained at Amsterdam
UMC. There was an excellent correlation between K1
and VT values obtained from the 60min scan and the
90min scan (K1: r
2¼ 1.00, slope¼ 1.05; VT: r2¼ 1.00,
slope¼ 1.04). Shortening the scan duration to 45 and
30min showed less reliable results, and an overestima-
tion of the VT values was observed (Figure 3). These
results suggest that shortening the scan duration to
60min has negligible effects on K1 and VT values and
is sufficient to obtain reliable estimates.
BPND values derived from SRTM showed good cor-
relations with plasma input derived DVR values for
both AD patients (test: r2¼ 0.85, slope¼ 0.72; retest:
r2¼ 0.86, slope¼ 0.76) and HCs (test: r2¼ 0.83,
slope¼ 0.73; retest: r2¼ 0.91, slope¼ 0.82) (see Figure
4). However, an underestimation of approximately
25% was observed. Data from UMCG showed similar
results (Supplementary Fig 3).
SUVr plots for test and retest for HC and AD
patients are shown in Supplementary Fig 4. The corre-
spondence between SUVr40–60min and SUVr50–60 with
plasma input derived DVR is presented in
Supplementary Fig 5 for AD patients and HCs.
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SUVr40–60 showed a slightly higher correlation with
DVR (plasma input) for both AD patients (test:
r2¼ 0.83, slope¼ 0.65; retest: r2¼ 0.89, slope¼
0.71) and HCs (test: r2¼ 0.90, slope¼ 0.73; retest:
r2¼ 0.84, slope¼ 0.74) compared to SUVr50–60
(AD: test: r2¼ 0.78, slope¼ 0.66; retest: r2¼ 0.73,
slope¼ 0.67/HCs: test: r2¼ 0.86, slope¼ 0.75; retest:
r2¼ 0.83, slope¼ 0.77). SUVr70–90min was also
assessed for HCs and had a better correspondence
with DVR (plasma input) compared to earlier time











































































Figure 2. Comparison of K1 and VT derived from 1T2k_VB model against K1 and VT derived from 2T4k_VB model apart for (a), (c)
AD patients and (b), (d) HCs using Amsterdam UMC data.
LOI: line of identity.















Figure 1. [11C]UCB-J metabolite fractions (mean SD) in arterial plasma at different time points.
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intervals (test: r2¼ 0.88, slope¼ 0.90; retest: r2¼ 0.90,
slope¼0.90, Supplementary Fig 6). All aforementioned
correlations were statistically significant (p< 0.05).
Test–retest analysis
Whole brain grey matter TRT for VT, plasma input
DVR and SRTM BPND were –2.2% 8.5, 0.4%
12.0 and –8.0% 10.2, respectively, averaged over all
subjects. For HC subjects, whole brain grey matter
TRT for VT, plasma input DVR and SRTM BPND
were –7.7% 4.3, –6.6% 6.1 and –8.2% 9.6,
respectively (Figure 5). For AD patients, the whole
brain grey matter TRT for the kinetic parameters VT,
plasma input DVR and SRTM BPND were –3.4%
8.1, 7.5% 12.7 and –7.6% 13.4, respectively. Figure
6 (Supplementary Fig 7 for UMCG data) and
Supplementary Fig 8 display the Bland Altman plots
for HCs and AD patients, for VT, DVR (plasma input)
and SRTM BPND using 60min data. The Bland
Altman plots for 90 min HC data is presented in
Supplementary Fig 9. For most of the regions, the
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Figure 3. Effect of scan duration reduction on (a), (b), (c) VT and (d), (e), (f) K1 estimations using Amsterdam UMC data.
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Figure 4. Comparison of SRTM-derived BPND against plasma input DVR for (a) AD patients and (b) HCs using Amsterdam UMC
data.






















































































Figure 5. (a), (c) Whole brain (grey matter) VT and plasma input DVR values derived from 1T2k_VB model are displayed for the test
and retest scan apart for HCs and AD patients; (b), (d) TRT for whole brain (grey matter) VT and plasma input DVR values are
displayed apart for HCs and AD patients using Amsterdam UMC data. Error bars indicate mean SD. **implies p< 0.01.
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TRT was less than 15% (1 SD) for VT, plasma input
DVR and SRTM BPND. Furthermore, all parameters
were systematically lower for most of the Hammers
regions in HC in the retest scan compared to the
test scan. TRT values for a few ROI are illustrated in
Table 1.
Figure 5 shows that there was a significant difference
between HCs and AD patients in whole brain grey
matter when using test scans and VT as a parameter
of interest (p¼ 0.007). There was one HC subject that
appeared as an outlier (>2 SD) in Figure 5(a), the sig-
nificant difference remained (p¼ 0.003) even if this sub-
ject was excluded from the analysis. However, the
significant difference was lost when the VT values
estimated from the retest scans were used for this
assessment (p¼ 0.54). Furthermore, lower plasma-
input DVR values (trend, 0.05> p> 0.1) were observed
in AD patients when compared to HC subjects for test
scans (p¼ 0.09, Figure 5(c)). Here again, there was one
HC subject with low plasma input DVR values appear-
ing to be an outlier (<2 SD), when this subject was
excluded from analysis, a significant difference was
observed between AD patients and HCs (p¼ 0.01).
This was not the case when the retest scans were used
for the same analysis (p¼ 0.41). In addition, no signif-
icant difference between the groups was observed in
neither the test nor the retest scans when using
SRTM BPND as the parameters of interest (p¼ 0.41;




















































































Note: % TRT = (retest - test)x100/average(test,retest) Note: % TRT = (retest - test)x100/average(test,retest)
Note: % TRT = (retest - test)x100/average(test,retest) Note: % TRT = (retest - test)x100/average(test,retest)
Note: % TRT = (retest - test)x100/average(test,retest) Note: % TRT = (retest - test)x100/average(test,retest)
Figure 6. Bland Altman %TRT plots for VT, SRTM BPND and plasma input DVR obtained using 60min PET data for (a), (c), (e) HCs
and (b), (d), (f) AD patients using Amsterdam UMC data.
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p¼ 0.76). Furthermore, a significant difference was
observed between the test and retest scan for whole
brain grey matter VT in HCs (p¼ 0.03). This was not
observed for AD patients.
The comparisons of VT, plasma input DVR and
SRTM BPND between HCs and AD patients for hip-
pocampus, medial temporal lobe and whole brain grey
matter are presented in Supplementary Fig 10.
Significant reductions of 20.9%, 17.3% and 16.9% in
VT were observed for AD patients for the regions: hip-
pocampus (AD: 16.3 1.3; HC: 20.6 3.0), MTL (AD:
17.7 1.6; HC: 21.4 2.8) and whole brain grey matter
(AD: 18.2 1.5; HC: 21.9 3.0) when the test scan was
used for the analysis (all p< 0.01), respectively. When
the retest scan was used for the same analysis, no sig-
nificant reduction was observed for these regions (all
p> 0.05). However, using the average VT of the test
and retest scan, a significant reduction of 11.8% in
VT was observed in the hippocampus for AD patients
(AD: 16.5 1.4; HC: 18.7 1.2) (p¼ 0.008). A trend
was observed in case of MTL and whole-brain VT, hip-
pocampus DVR and hippocampus BPND
(Supplementary Fig 10). The ICC for VT, DVR
(plasma input) and SRTM BPND was 0.94, 0.92 and
0.92 with 95% confident interval of 0.93–0.95, 0.90–
0.93 and 0.91–0.94, respectively.
Whole brain grey matter TRT averaged across all
subjects for SUVr40–60min and SUVr50–60min were 1
8.2% and 2 8.2%, respectively. For HCs, whole brain
grey matter TRT for SUVr40–60min was –3% 5.0 and
5% 9.1 for AD patients. Furthermore, whole brain
grey matter TRT for SUVr50–60min was 0% 5.4 for
HCs and 4% 10.3 for AD patients. The Bland
Altman plots for the SUVr40–60min and SUVr50–60min
for each subject group are presented in
Supplementary Fig 11. Supplementary Fig 12 illus-
trates the whole brain (grey matter) SUVr values for
test and retest for HCs and AD patients. No significant
difference between AD patients and HCs in neither the
test nor the retest scan in whole brain grey matter when
using SUVR40–60min (p¼ 0.13 for test, p¼ 0.97 for
retest) or SUVR50–60min (p¼ 0.45 for test, p¼ 0.85 for
retest) was observed.
Discussion
The current study investigated the kinetic analysis and
the TRT of the regional pharmacokinetic parameters
of [11C]UCB-J, a PET tracer binding to SV2A in the
brain. An one-tissue compartment model with a blood
volume parameter (1T2k_VB) was sufficient to describe
the in vivo kinetics of [11C]UCB-J. In addition, SRTM
could also be used to quantify [11C]UCB-J in a non-
invasive manner. Furthermore, we observed a mean 28-






























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































SRTM BPND less than 15% (1SD) averaged over all
subjects, implying that, in case of intervention studies
or drug trials, [11C]UCB-J can be used to quantify the
impact of the drug on SV2A, if the effect size of the
drug is higher than 15%.
The present findings with regard to the model pref-
erence are in line with another recent [11C]UCB-J
study.15 It was observed that both 1T2k_VB and
2T4k_VB compartment models had competing model
preferences based on AIC. However, the k3/k4 (BPND)
estimates from the 2T4k_VB model were highly unreli-
able. Moreover, K1 and VT estimates between the
1T2k_VB and 2T4k_VB models were highly correlated
as is illustrated in Figure 2 and Supplementary Fig 2.
This suggested that the use of 1T2k_VB model is suffi-
cient to evaluate the in vivo kinetics of [11C]UCB-J.
Furthermore, a decrease in the scan duration from 90
to 60min also had no significant effect neither on the
model preferences nor on the parameter estimations.
No significant difference was observed in the SO VTs
between the HCs and AD patients, supporting the use
of this region as a reference region. However, the kinet-
ic behaviour of the tracer in the region is quite different
from the rest of the brain regions. The influx of the
tracer in SO was much lower than in other brain
regions, resulting in a higher R1 value than usual
(Table 1). One of the assumptions for the implementa-
tion of the SRTM is that the non-specific compartment
in the reference region and the target region should be
equal, which is probably not fulfilled when using SO as
reference region. A recent study illustrated a higher
non-displaceable distribution volume (VND) estimation
when using SO as reference region, suggesting an
underestimation of the specific signal when performing
SRTM analysis.28 This indicates that SO might not be
an ideal reference region but could be used as a nor-
malization region. Further studies are necessary to val-
idate the use of SO or other possible reference regions
for proper quantification of [11C]UCB-J.
A good correlation between SRTM BPND values
and plasma input DVR values was observed, but with
approximately 25% underestimation. A possible expla-
nation for this phenomenon could be that VB correc-
tion is not present in the SRTM model since it is
assumed that the VB is rather constant between the
different brain regions. This might not be true for all
tracers and all regions, particularly in the present
situation, where the reference region seems to have dif-
ferent kinetics (lower tracer influx; K1) than the grey
matter ROIs. Another reason could be the significantly
lower activity in the SO, which resulted in noisy refer-
ence region TACs, which in turn led to fitting errors
(high standard errors for estimated parameters) in case
of SRTM. VT values are in general more forgiving in
this aspect and probably; therefore, plasma input
DVRs were slightly immune to the noise in the refer-
ence TACs. The observed TRT values were high for
reference region-based methods, and this could partial-
ly be explained by variability in the SO definition.
Although a clear trend of lower regional parametric
values in the AD patients was observed when com-
pared to HCs, a significant difference was observed in
the hippocampus, MTL and whole brain grey matter
only when using test scans and, the average of test and
retest scans VTs as the parameter of interest. The sig-
nificance remained even after excluding a possible out-
lier (by visual interpretation of the plots) from this
analysis. This HC subject had a very high VT value
for the corresponding regions, but nothing specifically
different/erroneous was observed in the data. Possibly,
the subject has a high physiological uptake; unfortu-
nately, there was no retest data available for this sub-
ject to assess this aspect. Similar comparisons using the
retest scans presented no significant differences
between groups (Supplementary Fig 10). SRTM
BPND values for HCs were higher in both, the test
and the retest scan when compared to AD patients.
However, this difference was less pronounced in the
retest scan. Unfortunately, it was not possible to use
all the values from each subject for this parameter,
since there was a high uncertainty observed when esti-
mating SRTM BPND (as discussed earlier). This could
also explain the higher inter-subject variability in both
groups when using SRTM BPND compared to other
parameters.
The current study observed a significant reduction
of 20.9% in hippocampus VT for AD patients when
compared to HCs. An earlier study by Chen et al.17
observed a higher reduction of SV2A in the hippocam-
pus, namely a reduction of 28% in hippocampus VT.
The AD patients in the current study were on average
10 years younger than the AD group in the study by
Chen et al.17 This could explain the lower percentage
reduction in the hippocampus in the current study.
Furthermore, the significant reduction of SV2A in the
hippocampus was only observed in the test scan and in
the average of test and retest scan. Moreover, we also
observed a trend (0.05> p> 0.1) in hippocampus when
using SRTM BPND values from the retest and when
using the average of SRTM BPND values from test
and retest scans. Chen et al.17 also observed a signifi-
cant reduction of synaptic density in AD patients when
SRTM2 BPND was used as the parameter of interest.
The observed difference in results based on the use
of test or retest data could be the result of the system-
atically lower parametric values for the retest scans
when compared to test scans in this study. Other
TRT studies of [11C]UCB-J imaging did not show a
systematic bias in one of the parameters.15 In contrast
to our study, previous studies, that reported no
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significant parameter estimation bias, performed the
test and retest scans on the same day. The reason for
finding a negative bias in the retest scan is still unclear.
No technical errors (e.g. related to data acquisition or
data processing), diurnal variations or changes in food
intake were detected that could explain this underesti-
mation. The AUCs of the SUV whole brain and metab-
olite corrected SUV plasma were also compared
between test and retest for both HCs and AD patients.
No significant difference in the SUV whole brain
uptake (p¼ 0.13) nor the metabolite corrected SUV
plasma activity (p¼ 0.80) was observed for HCs
between test and retest scans. Similarly, AD patients
also had no significant difference in SUV brain uptake
(p¼ 0.23) or metabolite-corrected SUV plasma activity
(p¼ 0.92). This also illustrates that the cause of system-
ic bias is not technical but most likely biological. A
possible hypothesis is that there is an increase in the
number of synaptic vesicles that are already trans-
ported to the membrane and ready to be released,
also called the readily releasable pool (RRP) of
vesicles.29 The increase in the number of synaptic
vesicles could be true for the test scan due to stress of
undergoing the procedure for the first time. The stress
levels would be lower for the second scan because the
subjects were already familiar with the procedure, in
particular for HC who are more aware of the situation.
However, we do not know the level of acute stress for
the first PET scan.
It should be noted that bias between test and retest
scans is not uncommon. The current study is not the
first study that observed a negative bias in the retest
scan. This was also observed in another study by Kim
et al..30 They found that the retest BPND values were
6% lower across all regions for [11C]DASB, which is a
tracer targeting serotonin transporters. The researchers
gave several possible explanations for this observation.
One of the explanations was that the negative bias in
the retest could be attributed to acute stress. Acute
stress activates several physiologic systems, which
leads to higher cortisol levels which modulate the sero-
tonergic neuronal activity.31,32 Furthermore, Leurquin-
Sterk et al.33 also observed a negative bias in the retest
scan for VT values for
18F-FPEB, which binds to
metabotropic glutamate subtype 5 receptor
(mGluR5). Their explanation was that VT does not
separate free and nonspecific compartments from the
specific compartment and, therefore, more sensitive to
errors in the input function. The researchers did not
observe the negative bias for BPND (k3/k4). In the cur-
rent study, the negative bias was observed in all the
parameter estimations but only for HCs (VT, plasma-
input derived DVR and SRTM BPND).
In case of the SUVr values, a high TRT was
observed irrespective of the time points (50–60min or
40–60min). However, no clear difference between the
patient and control group was observed suggesting that
this parameter might still be dominated by the signal
from the nonspecific compartment. It could also be the
case that SUVr did not reach equilibrium using earlier
time-points, as we saw a negative bias of 25% for
HCs and even more for AD patients. The negative
bias decreased to 10% using SUVr70–90min for HCs.
Since there was only 60min data available for AD
patients, it was not possible to perform group compar-
isons for SUVr70–90min. Further studies should focus on
assessing later time points in AD patients to assess the
applicability of SUVr70–90min.
An initial aim of the study was to validate the [11C]
UCB-J kinetics irrespective of differences between the
centres, i.e. to explore the generalizability of the find-
ings in a multicentre setting. Different scanners were
used in both centres, and there were subtle differences
in the metabolite measurement methodology between
the centres which can cause variability in the results.
Certain variability was observed in results of UMCG
and Amsterdam UMC data. As can be seen from
Figure 6 and Supplementary Fig 7, the main difference
was observed in case of VT values. A small non-
significant difference was observed in the whole blood
activity over time in case of UMCG blood data when
compared to the Amsterdam UMC blood data, which
could lead to some differences in parametric estima-
tions. However, it is difficult to conclude that if these
differences can cause significant variability in the
parameter estimations due to the small sample size of
UMCG data. However, it is important to note that the
results and conclusions do not differ with or without
the inclusion of UMCG data.
Conclusion
[11C]UCB-J kinetics can be well described by a revers-
ible single tissue compartment model with VB fraction
as a fit parameter. Reliable fits can be obtained with a
60 min scan duration for both plasma input and refer-
ence tissue models, which is in line with an earlier
study. The current study observed a mean 28-day
TRT for VT, plasma input derived DVR and SRTM-
derived BPND of <15% (1 SD) averaged over all sub-
jects, indicating adequate repeatability of [11C]UCB-J,
which is important for longitudinal studies and clinical
trials. SRTM-derived BPND correlates well with plasma
input derived DVR, although some negative bias in
both HC and AD subjects is seen.
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